'Mad Money' Uncover...
Health Care: Drugs
GlaxoSmithKline PLC (GSK: NYSE)
$52.65 0.44 | 0.84%
05/21/13 - 04:00 PM ET
2.35M / 2.77M
Vol / Avg. Vol:52.01 / 52.21
Open / Prev. Close:52.01 - 52.81
Today's Range:41.68 - 52.65
52 Wk Range:20.11%
Performance YTD:TheStreet Rating:
Portfolios with GSK
- Portfolio NameUser Type
- Usersamuel sandler kosher sausage
- ContributorStocks Rising On Unusual Vo...
- ProBill Miller - Legg Mason Ca...
- ProKen Fisher - Fisher Investm...
- Usercurrent holdings
- Contributor7 Big-Pharma Stocks With Un...
- Contributor10 Dividend Stocks Held by ...
- UserKAREL VON ZOETE
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
Latest GSK Headlines from TheStreet
- GlaxoSmithKline Stock Hits New 52-Week High (GSK) 05.21.13 | 11:05 am
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Aveo Screwed Up But Its Kidney Cancer Drug Is Real 05.15.13 | 08:05 am
- GlaxoSmithKline PLC Stock Buy Recommendation Reiterated (GSK) 05.14.13 | 10:05 am
- 4 Buy-Rated Dividend Stocks: HME, GSK, EPR, HPT 05.10.13 | 11:05 am
- GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) 05.07.13 | 09:05 am
- Buffett's Long-Term, High-Dividend Plays 05.04.13 | 03:05 am
- 3 Buy-Rated Dividend Stocks 05.01.13 | 11:05 am
- Aveo's Kidney Cancer Drug Won't Get FDA Panel OK 04.25.13 | 10:04 am
- GlaxoSmithKline Stock Hits New 52-Week High (GSK) 04.24.13 | 03:04 pm
Press Releases for GSK
- BREOâ¿¢ ELLIPTAâ¿¢ Gains US Approval For The Treatment Of COPD - PR Newswire 05.10.13 | 04:05 pm
- GlaxoSmithKline CFO Interviewed On Q1 2013 Financial Results - PR Newswire 04.24.13 | 07:04 am
- FDA Advisory Committee Recommends Approval Of BREOâ¿¢ ELLIPTAâ¿¢ For The Treatment Of COPD - PR Newswire 04.17.13 | 05:04 pm
- GlaxoSmithKline, Triangle Community Foundation Issue Call For Applications Totaling $400,000 In GSK IMPACT Awards - PR Newswire 04.17.13 | 11:04 am
- GlaxoSmithKline Issues Call For Applications Totaling $400,000 In GSK IMPACT Awards - PR Newswire 04.17.13 | 11:04 am
- GlaxoSmithKline And Liberty Property Trust/Synterra Partners Transform The Work Environment With The Opening Of Five Crescent Drive Today - PR Newswire 04.06.13 | 06:04 pm
- GlaxoSmithKline And Liberty Property Trust/Synterra Partners Transform The Work Environment With The Opening Of Five Crescent Drive - PR Newswire 04.05.13 | 10:04 am
- Texas A&M System And GlaxoSmithKline Receive U.S. Government Approval To Establish Influenza Vaccine Facility In Texas - PR Newswire 03.26.13 | 11:03 am
- Americans Rate Themselves And Their Communities As Healthy, Despite Research Showing The Opposite - PR Newswire 03.06.13 | 09:03 am
- GlaxoSmithKline Progresses Multi-city Discussion Focused On Improving The Health Of US Communities - PR Newswire 02.06.13 | 09:02 am
Partner Headlines for GSK
- Theravance, Glaxo, Elan Star In Biotech Soap Opera - Investor's Business Daily 05.13.13 | 05:05 pm
- Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD - Benzinga 05.10.13 | 12:05 pm
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In - Seeking Alpha 04.11.13 | 09:04 am
- Parexel Grows Earnings With Big Pharma Partnerships - Investor's Business Daily 04.04.13 | 02:04 pm
- Curing Parkinson's: The Alternative Approach - Is There Money To Be Made? - Seeking Alpha 04.04.13 | 09:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- 5 Dividends Stocks From Billionaire Ken Fisher - Seeking Alpha 03.28.13 | 09:03 am
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Valeant Earnings, Sales Top Estimates; Street Shrugs - Investor's Business Daily 02.28.13 | 05:02 pm
